Literature DB >> 27090054

Resistance to hypertension and high Cl- excretion in humans with SLC26A4 mutations.

B G Kim1, T-H Yoo2, J-E Yoo3, Y J Seo4, J Jung3, J Y Choi3.   

Abstract

Pendrin is a membrane transporter encoded by solute carrier family26A4 (SLC26A4). Mutations in this gene are known to cause hearing loss, and recent data from animal studies indicate a link between pendrin expression and hypertension; although, this association in humans is unclear. To clarify this issue, we investigated the influence of pendrin on blood pressure by analyzing demographic and biochemical data - including blood pressure and urinary electrolyte excretion - in patients with bi-allelic SLC26A4 mutations. Systolic and diastolic blood pressure and the left ventricular hypertrophy index were lower in subjects with pendrin mutations than in controls. In addition, fractional excretion of Na+ and Cl- was increased and serum renin, angiotensin I and II levels were higher in subjects with pendrin mutations as compared to controls. Thus, patients with impaired pendrin function are likely to be resistant to high blood pressure due to enhanced urinary Na+ /Cl- excretion. These results suggest that pendrin may regulate blood pressure through increased urinary salt excretion.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  SLC26A4; blood pressure; electrolyte; hypertension; pendrin; urine

Mesh:

Substances:

Year:  2016        PMID: 27090054     DOI: 10.1111/cge.12789

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  9 in total

Review 1.  The Renal Physiology of Pendrin-Positive Intercalated Cells.

Authors:  Susan M Wall; Jill W Verlander; Cesar A Romero
Journal:  Physiol Rev       Date:  2020-07-01       Impact factor: 37.312

2.  Pendrin-null mice develop severe hypokalemia following dietary Na+ and K+ restriction: role of ENaC.

Authors:  Truyen D Pham; Anthony J Elengickal; Jill W Verlander; Lama Al-Qusairi; Chao Chen; Delaney C Abood; Spencer A King; Johannes Loffing; Paul A Welling; Susan M Wall
Journal:  Am J Physiol Renal Physiol       Date:  2022-02-28

3.  Aldosterone Is Essential for Angiotensin II-Induced Upregulation of Pendrin.

Authors:  Daigoro Hirohama; Nobuhiro Ayuzawa; Kohei Ueda; Mitsuhiro Nishimoto; Wakako Kawarazaki; Atsushi Watanabe; Tatsuo Shimosawa; Takeshi Marumo; Shigeru Shibata; Toshiro Fujita
Journal:  J Am Soc Nephrol       Date:  2017-10-11       Impact factor: 10.121

Review 4.  Regulation of Blood Pressure and Salt Balance By Pendrin-Positive Intercalated Cells: Donald Seldin Lecture 2020.

Authors:  Susan M Wall
Journal:  Hypertension       Date:  2022-02-03       Impact factor: 10.190

Review 5.  Renal intercalated cells and blood pressure regulation.

Authors:  Susan M Wall
Journal:  Kidney Res Clin Pract       Date:  2017-12-31

6.  Search for New Candidate Genes Involved in the Comorbidity of Asthma and Hypertension Based on Automatic Analysis of Scientific Literature.

Authors:  Olga V Saik; Pavel S Demenkov; Timofey V Ivanisenko; Elena Yu Bragina; Maxim B Freidin; Victor E Dosenko; Olga I Zolotareva; Evgeniy L Choynzonov; Ralf Hofestaedt; Vladimir A Ivanisenko
Journal:  J Integr Bioinform       Date:  2018-12-25

7.  Inhibiting SLC26A4 reverses cardiac hypertrophy in H9C2 cells and in rats.

Authors:  Liqun Tang; Xiaoqin Yu; Yangyang Zheng; Ning Zhou
Journal:  PeerJ       Date:  2020-01-21       Impact factor: 2.984

Review 8.  The Roles of Solute Carriers in Auditory Function.

Authors:  Fuping Qian; Xiaoge Jiang; Renjie Chai; Dong Liu
Journal:  Front Genet       Date:  2022-01-26       Impact factor: 4.599

9.  Characterization of pendrin in urinary extracellular vesicles in a rat model of aldosterone excess and in human primary aldosteronism.

Authors:  Fumika Ochiai-Homma; Emiko Kuribayashi-Okuma; Yuya Tsurutani; Kenichi Ishizawa; Wataru Fujii; Kohei Odajima; Mika Kawagoe; Yoshihiro Tomomitsu; Masataka Murakawa; Shinichiro Asakawa; Daigoro Hirohama; Michito Nagura; Shigeyuki Arai; Osamu Yamazaki; Yoshifuru Tamura; Yoshihide Fujigaki; Tetsuo Nishikawa; Shigeru Shibata
Journal:  Hypertens Res       Date:  2021-07-29       Impact factor: 3.872

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.